KOSDAQ · 215600 · Biotech & Pharma · ₩215600

SillaJen신라젠

215600 · KOSDAQ · ₩215600 · 신라젠

₩2,130▼ ₩10 (0.47%)End-of-day · Oct 27, 2026 · End-of-day prices.

Trade

Sell Buy

Filings

Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획승인신청) (덱시부프로펜주(WS2405)의 제 1상 임상시험 계획 승인 신청)Sep 15, 2026Open on DART
[Amended] Notice of Stock Purchase Option Grant[기재정정]주식매수선택권부여에관한신고Sep 3, 2026Open on DART
[Amended] Notice of Stock Purchase Option Grant[기재정정]주식매수선택권부여에관한신고Sep 3, 2026Open on DART
Half-year report (Jun 2026)반기보고서 (2026.06)Aug 14, 2026Open on DART
Amended: Quarterly report (Mar 2026)[기재정정]분기보고서 (2026.03)Aug 14, 2026Open on DART
Quarterly report (Mar 2026)분기보고서 (2026.03)May 15, 2026Open on DART
Change of CEO대표이사변경Mar 27, 2026Open on DART
Annual general meeting results정기주주총회결과Mar 27, 2026Open on DART
Audit report submitted감사보고서제출Mar 19, 2026Open on DART
Annual report (Dec 2025)사업보고서 (2025.12)Mar 19, 2026Open on DART
Reference Document for Proxy Solicitation of Voting Rights의결권대리행사권유참고서류Mar 5, 2026Open on DART
Notice of Reason for Concentrated Shareholders' Meeting Date주주총회집중일개최사유신고Mar 4, 2026Open on DART
Shareholders' meeting called주주총회소집결의Mar 4, 2026Open on DART
Notice of shareholders' meeting주주총회소집공고Mar 4, 2026Open on DART
[Amended] Notice of Stock Purchase Option Grant[기재정정]주식매수선택권부여에관한신고Mar 4, 2026Open on DART
Notice on Grant of Stock Purchase Options주식매수선택권부여에관한신고Mar 4, 2026Open on DART
Change in Revenue or Profit/Loss Structure of 30% or More (15% or More for Large Companies)매출액또는손익구조30%(대규모법인은15%)이상변동Feb 5, 2026Open on DART
Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Dec 15, 2025Open on DART
Quarterly report (Sep 2025)분기보고서 (2025.09)Nov 14, 2025Open on DART
Investor relations (IR) event기업설명회(IR)개최Oct 20, 2025Open on DART
Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획변경승인) (진행성 고형암 또는 재발성/불응성 급성 골수성 백혈병 환자를 대상으로 BAL0891의 단일요법 및 항암화학요법 또는 티스렐리주맙과의 병용요법에 대한 미국 FDA 제1상 임상시험 계획(IND) 변경 승인)Oct 10, 2025Open on DART
Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항(임상시험계획변경승인) (진행성 고형암 또는 재발성/불응성 급성 골수성 백혈병 환자를 대상으로 BAL0891의 단일요법 및 항암화학요법 또는 티스렐리주맙과의 병용요법에 대한 식품의약품안전처 제1상 임상시험 계획 변경 승인)Sep 23, 2025Open on DART
Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획변경승인) (진행성 고형암 또는 재발성/불응성 급성 골수성 백혈병 환자를 대상으로 BAL0891의 단일요법 및 항암화학요법 및 티스렐리주맙과의 병용요법에 대한 식품의약품안전처 제1상 임상시험 계획 변경 승인)Sep 9, 2025Open on DART
Half-year report (Jun 2025)반기보고서 (2025.06)Aug 14, 2025Open on DART
Amended: Annual report (Dec 2024)[기재정정]사업보고서 (2024.12)Aug 14, 2025Open on DART
Designation as Unfaithful Disclosure Company (Disclosure Change)불성실공시법인지정 (공시변경)Aug 5, 2025Open on DART
Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획변경승인신청) (진행성 고형암 또는 재발성/불응성 급성 골수성 백혈병 환자를 대상으로 BAL0891의 단일요법 및 항암화학요법 및 티스렐리주맙과의 병용요법에 대한 미국 FDA 제1상 임상시험 계획 변경 승인 신청)Jul 15, 2025Open on DART
Notice of Designation as Unfaithful Disclosure Entity (Disclosure Change)불성실공시법인지정예고 (공시변경)Jul 11, 2025Open on DART
Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 2, 2025Open on DART
Merger Completion Report (Merger)합병등종료보고서(합병)Jul 1, 2025Open on DART
Merger Completion Report (Asset Acquisition and Transfer)합병등종료보고서(자산양수도)Jun 23, 2025Open on DART
Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획변경승인신청) (진행성 고형암 또는 재발성/불응성 급성 골수성 백혈병 환자를 대상으로 BAL0891의 단일요법 및 항암화학요법 및 티스렐리주맙과의 병용요법에 대한 식품의약품안전처 제1상 임상시험 계획 변경 승인 신청)Jun 19, 2025Open on DART
Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획변경승인) (진행성 고형암 또는 재발성/불응성 급성 골수성 백혈병 환자를 대상으로 BAL0891의 단일요법 및 항암화학요법과의 병용요법에 대한 식품의약품안전처(MFDS) 제1상 임상시험 계획(IND) 변경 승인)Jun 13, 2025Open on DART
Other management matters기타경영사항(자율공시) (소규모 합병 승인 이사회 결의(주주총회 갈음) 결과 보고)May 29, 2025Open on DART
[Amended] Notice of Stock Purchase Option Grant[기재정정]주식매수선택권부여에관한신고May 29, 2025Open on DART
[Amended] Notice of Stock Purchase Option Grant[기재정정]주식매수선택권부여에관한신고May 29, 2025Open on DART
[Amended] Notice of Stock Purchase Option Grant[기재정정]주식매수선택권부여에관한신고May 29, 2025Open on DART
[Amended Filing] Major Matters Report (Decision on Transfer of Equity Securities of Another Company)[기재정정]주요사항보고서(타법인주식및출자증권양도결정)May 29, 2025Open on DART
Amended: Merger decision[기재정정]주요사항보고서(회사합병결정)May 27, 2025Open on DART
Amended: Quarterly report (Mar 2025)[기재정정]분기보고서 (2025.03)May 22, 2025Open on DART
Quarterly report (Mar 2025)분기보고서 (2025.03)May 15, 2025Open on DART
Amended: Annual report (Dec 2024)[기재정정]사업보고서 (2024.12)May 15, 2025Open on DART
Amended attachment: Merger decision[첨부정정]주요사항보고서(회사합병결정)Apr 29, 2025Open on DART
Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Apr 24, 2025Open on DART
Merger decision주요사항보고서(회사합병결정)Apr 24, 2025Open on DART
Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항 (유사분열 체크포인트 억제제(MCI) 후보물질의 기술 도입 계약 체결)Apr 22, 2025Open on DART
Major management matter relevant to investors투자판단관련주요경영사항 (유사분열 체크포인트 억제제(MCI) BAL0891의 PH1128(물질특허)와 P1129(바이오마커특허) 특허권 취득 결정)Apr 21, 2025Open on DART
Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항 (유사분열 체크포인트 억제제(MCI) 후보물질의 기술 도입 계약 체결)Apr 21, 2025Open on DART
Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획변경승인) (진행성 고형암 또는 재발성/불응성 급성 골수성 백혈병 환자를 대상으로 BAL0891의 단일요법 및 항암화학요법과의 병용요법에 대한 미국 FDA 제1상 임상시험 계획(IND) 변경 승인)Apr 21, 2025Open on DART
Amended: Rights offering (paid-in capital increase) decision[기재정정]주요사항보고서(유상증자결정)Apr 17, 2025Open on DART

Titles in Korean until English translations are added.

Also known as: SillaJen / 신라젠 / 215600 / KRX:215600

Source: KRX statistical information